Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
| Dec '25 | Jun '25 | Dec '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.14 | 1.49 | 1.31 | 1.38 |
+1 more quarter Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
17.10% | 17.00% | 17.52% | 17.92% | |
Debt/Equity |
0.24 | 0.23 | 0.25 | 0.25 | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.04) | (0.05) | (0.56) | (1.40) | |
Intangible Assets out of Total Assets |
0.13 | 0.05 | 0.05 | 0.05 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
1.77 | (2.04) | 3.78 | (0.16) | |
Working Capital |
2.42 | 9.30 | 5.71 | 7.20 | |
Capital Expenditures |
(0.14) | (0.09) | (1.85) | (2.18) | |
Net Current Asset Value |
1.09 | 8.64 | 5.05 | 7.14 | |
| Other line items | |||||
Quick Ratio |
0.60 | 0.72 | 0.69 | 0.67 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
6.93 | — | — | — | |
Average Payables |
6.29 | — | — | — | |
Average Inventory |
6.81 | — | — | — | |
Average Assets |
65.60 | — | — | — | |
Average Common Equity |
45.27 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates